David D. Waters, M.D. Chief, Division of Cardiology at San Francisco General Hospital Professor of Medicine in Residence mail: San Francisco General Hospital 1001 Potrero Ave., 5G1 UCSF Box 0846 San Francisco, CA 94110 phone: (415) 206-8320 fax: (415) 206-5100 email: dwaters@medsfgh.ucsf.edu

Education

University of Western Ontario, London, Ontario, Premedicine and Medicine, 1964 1970
Pauline Johnson Collegiate, Brantford, Ontario, 1960 1964

Professional Experience

Chief, Division of Cardiology, San Francisco General Hospital, 1999 - Present

Maurice Eliaser Jr. Distinguished Professor of Medicine (in Residence), University of California San Francisco, 1999 - Present

Chief, Division of Cardiology, Hartford Hospital, 1993-99

Professor of Medicine (Cardiology), University of Connecticut, 1993-99

Chief, Division of Cardiology, Univ. of Connecticut Health Center, 1997-1998

Staff Cardiologist, Montreal Heart Institute, 1976 1992

Director, Research Center, Montreal Heart Institute, 1986 90

Professeur agrégé de clinique, Département de médecine, Université de Montréal, 1986-1992

Awards

Joseph Dvorkin Visiting Professor, University of Alberta 1990
Canadian Heart Foundation Fellowship 1975
Emory University School of Medicine Lloyd Hyde Research Award 1975
University of Western Ontario J.B. Campbell Scholarship in Medicine 1970
University of Western Ontario Admission Scholarship 1964

Research Interests

Dr. Waters early research involved vasospastic angina, risk stratification in acute coronary syndromes and trials of antiplatelet and antithrombotic therapy for unstable angina. More recently he has directed clinical trials assessing the effect of a calcium channel blocker, a statin, antioxidant vitamins and hormone replacement upon the progression of coronary disease, as well as other trials of cholesterol-lowering therapies.

Selected Recent Publications

1. Waters D, Lespérance J, Francetich M, Causey D, Théroux P, Hudon G, Lemarbre L, Reitman M, Chiang YK, Joyal M, Gosselin G, Dyrda I, Macer J, Havel RJ. A controlled clinical trial to assess the effect of a calcium channel blocker upon the progression of coronary atherosclerosis. Circulation 1990;82:1940-1953
   
   
2. Bosch X, Théroux P, Pelletier GB, Sanz G, Roy D, Waters D. Clinical and angiographic features and prognostic significance of early post infarction angina with and without electrocardiographic signs of transient ischemia. Am J Med 1991;91:493-501
   
   
3. Théroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992;327:141-145
   
   
4. Théroux P, Waters D, Qiu S, McCans, J, de Guise P, Juneau M, Pelletier GB, Lam J. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993;88:2045-2048
   
   
5. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762-2770
   
   
6. Lacoste LL, Lam JYT, Hung J, Waters D. Oral verapamil inhibits platelet thrombus formation in humans. Circulation 1994;89:630-634
   
   
7. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lespérance J, and the CCAIT Study Group. Effect of monotherapy with an HMG CoA reductase inhibitor upon the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-968
   
   
8. Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T, Lespérance J, and the CCAIT Study Group. Effect of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation 1995;92:2404-2410
   
   
9. Wu AHB, Abbas SA, Green S, Pearsall L, Dhakam S, Azar R, Onoroski M, Senaie A, McKay RG, Waters D. Prognostic value of cardiac troponin T in unstable angina pectoris. Am J Cardiol 1995;76:970-972
   
   
10. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-3177
    
    
11. Waters D, Lespérance J, Gladstone P, Boccuzzi SJ, Cook T, Hudgin R, Krip G, Higginson L and the CCAIT Study Group. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. Circulation 1996;94:614-621
    
    
12. Waters D, Azar RR. Low molecular-weight heparins in the treatment of unstable angina: a better mousetrap? Circulation 1997;96:3-5
    
    
13. Waters D. Cholesterol lowering: should it continue to be the last thing we do? Circulation 1999;99:3215-3217
    
    
14. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS, for the AVERT Investigators. Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70-76
    
    
15. Giri S, Thompson PD, Kiernan FJ, Clive J, Fram DB, Mitchel JF, Hirst JA, McKay RG, Waters DD. Clinical and angiographic characteristics of exertion-related acute myocardial infarction. JAMA 1999;282:1731-1736
    
    
16. Waters DD, Azar RR. Postscripts from the Post Coronary Artery Bypass Graft Trial: the sustained benefit of more aggressive cholesterol lowering and the enigma of low dose anticoagulation. Circulation 2000;102:1-3
    
    
17. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529
    
    
18. Azar RR, Rinfret S, Théroux P, Stone PH, Dakshinamurthy R, Feng YJ, Wu AHB, Rangé G, Waters DD. A randomized placebo controlled trial to assess the efficacy of anti-inflammatory therapy with methylprednisolone in unstable angina (MUNA Trial). Eur Heart J 2000;21:2026-2032
    
    
19. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA 2001;265:1711-1718
    
    
20. Giri S, Shaw LJ, Murthy DR, Travin MI, Miller DD, Hachamovitch R, Borges-Neto S, Berman DS, Waters DD, Heller HV. Cardiac risk stratification using stress SPECT myocardial perfusion imaging in patients with diabetes mellitus. Circulation 2002;105:32-40
    
    
21. Hsue PY, Salinas C, Bolger AF, Benowitz NL, Waters DD. Acute aortic dissection related to crack cocaine. Circulation 2002;105:1592-1595
    
    
22. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley SB, Herd A, Khan S, Newby K, Waters D, Vittinghoff E, Wenger N, for the HERS Research Group. Cardiovascular outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002;208:49-57
    
    
23. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T, for the MIRACL Study Investigators. Effects of atorvastatin on stroke in patients with unstable angina or non-Q wave myocardial infarction: a MIRACL substudy. Circulation 2002;106:1690-1695
    
    
24. Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, Ouyang P, Thompson P, Tardif JC, Higginson L, Bittner V, Steffes M, Gordon DJ, Proschan M, Younes N, Verter JI. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: the Women.s Angiographic Vitamin and Estrogen (WAVE) Trial. JAMA 2002;288:2432-2440
    
    
25. Jha A, Varosy PD, Kanaya AM, Hunninghake DB, Hlatky MA, Waters DD, Furberg CD, Shlipak MG. Differences in medical care and disease outcomes among black and white women with heart disease. Circulation 2003;108:1089-1094
    
    
26. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C, for the TNT Steering Committee members and investigators. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004;93:154-158
    
    
27. Hsue PY, Giri K, Erickson S, MacGregor JS, Younis Y, Shergill A, Waters DD. Clinical features of acute coronary syndromes in patients with Human Immunodeficiency Virus infection. Circulation 2004;109:316-319
    
    
28. Waters DD, Gordon D, Rossouw JE, Cannon RO 3rd, Collins P, Herrington DM, Hsia J, Langer R, Mosca L, Ouyang P, Sopko G, Stefanick ML. Women.s Ischemic Syndrome Evaluation: current status and future research directions. Report of the National Heart Lung Blood Institute (NHLBI) Workshop. Section 4: Lessons from hormone replacement trials. Circulation 2004;109:e53-55
    
    
29. Bairey Merz N, Bonow RO, Sopko G, Balaban RS, Cannon RO, Gordon D, Hand MM, Hayes SN, Lewis JF, Long T, Monolio TA, Maseri A, Nabel EG, Desvigne Nickens P, Pepine CJ, Redberg RF, Rossouw JE, Selker HP, Shaw LJ, Waters DD. Women.s Ischemic Syndrome Evaluation: current status and future research directions. Report of the National Heart Lung Blood Institute (NHLBI) Workshop. Executive summary. Circulation 2004;109:805-807
    
    
30. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG, Waters DD. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004;109:1603-1608
    
    
31. Howard BV, Hsia J, Ouyang P, Van Voorhees L, Lindsay J, Silverman A, Alderman EL, Triputti M, Waters DD. Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance. Circulation 2004;110:201-206